Original paper
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Abstract
Riociguat is a soluble, guanylate cyclase stimulator, approved for pulmonary arterial hypertension. In the 12-week PATENT-1 study, riociguat was well tolerated and improved several clinically relevant end-points in patients with pulmonary arterial hypertension who were treatment naïve or had been pretreated with endothelin-receptor antagonists or prostanoids. The PATENT-2 open-label extension evaluated the long-term safety and efficacy of...
Paper Details
Title
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)
Published Date
Jan 22, 2015
Journal
Volume
45
Issue
5
Pages
1303 - 1313
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History